Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5050554 | 0.88 | CTRB1 (0.53) | MEN1KMT2ANPC1LMNANPSR1 | |
| SCHEMBL3824430 | 0.86 | CMA1 (0.52) | MEN1KMT2ANPC1MCL1TACR1 | |
| SCHEMBL28625318 | 0.81 | KMT2A (0.51) | MEN1KMT2ANPC1LMNANPSR1 | |
| SCHEMBL28625316 | 0.80 | ALDH1A1 (0.52) | MEN1KMT2ANPC1LMNANPSR1 | |
| SCHEMBL29006896 | 0.78 | NPC1 (0.72) | MEN1KMT2ANPC1LMNANPSR1 | |
| SCHEMBL2072188 | 0.78 | CTSC (0.53) | MEN1KMT2ANPC1LMNANPSR1 | |
| SCHEMBL2072191 | 0.78 | CTSC (0.53) | MEN1KMT2ANPC1LMNANPSR1 | |
| SCHEMBL10432864 | 0.78 | PPARG (0.53) | MEN1KMT2ANPC1LMNAALDH1A1 | |
| SCHEMBL2073446 | 0.77 | CTSC (0.48) | MEN1KMT2ANPC1LMNANPSR1 | |
| SCHEMBL2073444 | 0.77 | CTSC (0.48) | MEN1KMT2ANPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | MEN1 841/4885KMT2A 3838/4885NPC1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.